Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen.

Summary: Tamoxifen is a life-saving drug for breast cancer, but it is known to increase the risk of endometrial polyps (growths in the uterine lining) in postmenopausal women. Doctors need to know if these polyps are likely to turn into cancer. In this study, researchers compared polyps from women taking Tamoxifen against polyps from women not taking hormones, as well as samples from women with uterine cancer. They looked for specific proteins: one that signals cell speed (Ki-67), one that suppresses tumors (p53), and one that builds blood vessels (CD31).

The findings showed that while Tamoxifen-associated polyps do have faster cell growth than normal tissue, they do not show the dangerous blood vessel formation or the loss of tumor-suppressor proteins seen in cancer. This suggests that while Tamoxifen stimulates cell activity in polyps, it does not necessarily trigger the aggressive changes typical of malignancy.